USC researchers identify DNA mutation that occurs at beginning point of T-cell lymphomaJune 12, 2009Researchers at the Keck School of Medicine of the University of Southern California (USC) have identified a key mechanism that causes chromosomes within blood cells to break-an occurrence that marks the first step in the development of human lymphoma. The study provides researchers with the clearest insight yet into why these breakages-called chromosomal translocations-occur at a specific points in the chromosome, says principal investigator Michael R. Lieber, M.D., Ph.D., Rita and Edward Polusky Professor in Basic Cancer Research at the Keck School of Medicine. The study appears as the featured cover article in the June 12 issue of the journal Molecular Cell. The study is the second led by Lieber to appear on the cover of a Cell journal in the past six months. "The new findings go to the heart of why cancers begin. This is an opportunity to see the very beginning step of human lymphoma," Lieber says. "With this information, we can now begin to look at ways to interfere with this process in order to stop the lymphoma and to develop more targeted therapies for treatment." There are two types of lymphoma: B cell lymphomas and T cell lymphomas. Both B cells and T cells perform vital functions in the immune system by creating antibodies and destroying virus-infected cells. However, the beginning point, or inception, of most human lymphomas occurs when two chromosomes break and the resulting fragments are reassembled in an exchange. Researchers specifically looked at T cell acute lymphoblastic lymphomas (ALL). ALL accounts for half of all childhood cancers under the age of five, and T cell ALL represents about 10 percent of ALL. The USC scientists identified a specific enzyme known as the RAG complex that occasionally cuts the chromosome at an off-target site, causing lymphocyte (blood) cells to proliferate uncontrollably. They showed that the RAG complex selects the wrong target largely because the proteins in which the wrong chromosome is wrapped (called chromatin) lures the RAG complex to the wrong site. "The immune system is very good at its job," Lieber says. "More than ninety-nine percent of the time it gets it right, but it only takes one mistake in one of a hundred million cells to cause a problem. " The paper follows a similar study, published in the December issue of the journal Cell, in which Lieber and colleagues determined how the most common chromosomal translocation in B cell lymphoma occurs. Researchers at USC have been working for many years to understand the underlying mechanisms that cause blood cancers. "The goal is to understand translocations in various different forms of lymphoma," Lieber says. "The two papers cover more than half of all human lymphomas. That represents a major step forward in understanding this disease." University of Southern California |
|||||||||||||||||||||
| Related Lymphoma Current Events and Lymphoma News Articles Approved lymphoma drug shows promise in early tests against bone cancer A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. Immunotherapy demonstrates long-term success in treating lymphoma Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). Exercise is good medicine for lymphoma patients A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta researchers have found. Childhood cancer survivors experience suicidal thoughts decades after diagnosis Adult survivors of childhood cancer have an increased risk for suicidal thoughts, even decades after their cancer treatments ended, according to a study led by Dana-Farber Cancer Institute scientists. New therapy for vasculitis will help patients avoid infertility and cancer Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy. Studying cancer in pet dogs to find new treatments for human patients A team of scientists at the National Cancer Institute (NCI) in Bethesda, USA, says that studying pet dogs with cancer could yield valuable information on how to diagnose and treat human cancers. Scientists identify genetic cause of previously undefined primary immune deficiency disease Researchers at the National Institutes of Health have identified a genetic mutation that accounts for a perplexing condition found in people with an inherited immunodeficiency. Certain cancers more common among HIV patients than non-HIV patients Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s. Identification of highly radiosensitive patients may lead to side effect-free radiotherapy An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics. Experimental drug lets B cells live and lymphoma cells die An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology. More Lymphoma Current Events and Lymphoma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||